HawkInsight

  • Contact Us
  • App
  • English

German pharmaceutical developer Evotec SE has received an offer from Nasdaq-listed biotech company Halozyme Therapeutics Inc. The potential valuation of the company is 2 billion euros ($2.1 billion).

German pharmaceutical developer Evotec SE has received an offer from Nasdaq-listed biotech company Halozyme Therapeutics Inc.

The potential valuation of the company is 2 billion euros ($2.1 billion).

Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.

NewFlashHawk Insight
More